Search Results for

Showing 1 - 10 of 51 results
  1. OCT paper press release

    Embargoed until Dec. 7, 12pm EDT Media contact: Marisa Lavine   +1.240.221.2923   mlavine@arvo.org                                                                                                                                                                                                                                New study finds federally-funded technology saved Medicare $9 billion Rockville, Md. — A new study quantifying a 21-fold return on investment suggests an e

  2. AMPC Candidates

    All candidate bios and nomination statements are available on the official ballots

  3. Professional Development and Education Committee

    Professional Development and Education Committee Professional Development and Education Committee Description The Professional Development and Education Committee (PDEC) provides oversight and evaluation of ARVO's educational and training activities, including ARVO-sponsored/cosponsored and conferences, courses, symposia, workshops, tutorials, etc. and online education such as webinars, podcasts, courses, etc. Activities Provides oversight for ARVO's portfolio of education and training pr

  4. Board of Trustees

    Board of Trustees The Board of Trustees is comprised of elected members from ARVO's 13 Scientific Sections along with elected and trustee-appointed officers. The president and vice president(s) are elected from within the Board each year. The executive vice president is elected by the general membership to a five-year term and is a voting member of the Board of Trustees. The ARVO executive director serves as an ex officio member of the Board. For more information on Board of Trustee duties,

  5. Invited speakers

    Invited speakers Bettina Ryll Richard D. Carvajal Invited Speakers Sponsors

  6. Spotlight on members: Spark

    Spotlight on members From hospital funding to FDA approval Spark Therapeutics develops gene therapy for inherited retinal blindness After over two decades of research and development in gene therapy, Katherine A. High, MD, co-founder, president and chief scientific officer of Spark Therapeutics, is breathing a big sigh of relief this fall. On Oct. 12, the Food and Drug Administration unanimously voted to approve voretigene neparvovec, Spark Therapeutics' gene therapy treatment for inherited b

  7. Organizers

    Organizers Conference Organizers Committee Members

  8. Journals and Publications landing

    Journals and Publications ARVO's Open Access Journals EyeFind The Association for Research in Vision and Ophthalmology (ARVO) and the Eye Bank Association of America (EBAA) recognize a need to improve the exchange of information between scientists and the eye banks that supply human donor eye tissues for their research. Working collaboratively, ARVO members and EBAA members developed an online tool to facilitate better communication. ARVONews ARVO Insight Funding Guide More resources